TRACON Pharmaceuticals announces FDA approval for CTLA-4 antibody YH001 for treating sarcoma in combination with envafolimabProactive Investors • 08/29/22
TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with EnvafolimabGlobeNewsWire • 08/29/22
TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
TRACON Pharmaceuticals ends 2Q with strong cash runway to support key trialsProactive Investors • 08/10/22
TRACON Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/10/22
TRACON Pharmaceuticals says ENVASARC trial gets recommendation to proceed as plannedProactive Investors • 08/10/22
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal TrialGlobeNewsWire • 08/10/22
TRACON Pharmaceuticals submits new drug application for the treatment of sarcoma patients in combination with envafolimabProactive Investors • 08/08/22
TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with EnvafolimabGlobeNewsWire • 08/08/22
TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022GlobeNewsWire • 07/27/22
TRACON Pharmaceuticals enrols 36th patient at ENVASARC trial triggering 4Q interim efficacy analysisProactive Investors • 07/26/22
TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth QuarterGlobeNewsWire • 07/26/22
4 Stocks Under $2 Insiders Are Aggressively Buying: NEXGEL, eFFECTOR Therapeutics And MoreBenzinga • 06/28/22
TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/16/22
TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/12/22
TRACON Pharmaceuticals says it is on track to release new efficacy data from ENVASARC protocol later this yearProactive Investors • 05/11/22
TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/11/22
TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022GlobeNewsWire • 05/04/22
TRACON Pharmaceuticals receives amended ENVASARC protocol approval for its US and UK clinical sitesProactive Investors • 04/19/22
TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K.GlobeNewsWire • 04/19/22
TRACON Pharmaceuticals to Present at the Maxim Group 2022 Virtual Growth ConferenceGlobeNewsWire • 03/23/22
TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/16/22
TRACON Pharmaceuticals ends FY2021 with $24.1M in the bank; reveals key milestones for 2022Proactive Investors • 03/15/22